CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Jing GaoZhengyi WangWenqing JiangYanni ZhangZhen MengYanling NiuZhen ShengChan ChenXuejun LiuXi ChenChanjuan LiuKeren JiaCheng ZhangHaiyan LiaoJaeho JungEunsil SungHyejin ChungJingwu Z ZhangAndrew X ZhuLin ShenPublished in: Journal for immunotherapy of cancer (2023)
T cells in tumor microenvironment to avoid the risk of liver toxicity and systemic immune response.